Early phase III data indicate Pfizer/BioNTech’s COVID-19 vaccine 90% effective

Analysis of the phase III trial of Pfizer and BioNTech’s COVID-19 vaccine (BNT162b2; n=43,538), suggests an efficacy rate of >90% in subjects 7 days after receiving the second dose. During the trial, 94 subjects developed the novel coronavirus, SARS-CoV-2, which causes COVID-19.

Source:

PharmaTimes